US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 2026

March 2021 | 240 pages | ID: U281230F8C7EEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 2026' Report highlights:

• US Cancer Biosimilar Market Opportunity: > US$ 15 Billion By 2026
• Currently 29 Cancer Biosimilar Approved In US Market
• Pricing & Dosage Insight On More Than 10 Cancer Biosimilar Commercially Available In US Market
• Cancer Biosimilar In Clinical Trials: > 10 Biosimilars
• Comprehensive Insight On Cancer Biosimilar Clinical Trials Insight By Company & Indication
• Insight On 15 Potential Cancer Biosimilars Market Opportunity By Popular Drugs Patent Expiry: Erbitux, Vectibix, Yervoy, Trodelvy, Perjeta, Gazyva, Darzlex, Xgeva, Cyramza, Kadcyla, Opdivo, Tagraxofusp, Tecentriq, Keytruda, Imfinzi

The US cancer biosimilar market landscape is inclined towards entering the time of a splendid change. In the past few years, the country has observed a high influx in the number of biosimilar products for the benefit of the patient population, as the price of the branded drugs in the country such as immunotherapy and many more were in rise. Therefore, the arrival of cancer biosimilar drug market in the country has played an important role in contributing a significant share in the overall cancer therapeutics market in the country. It can be observed for US cancer biosimilar market that despite of having tough competition, the market has been able to sustain the growth which is however very critical as millions of patients were highly dependent on the regulatory benefits of the market, thus promoting the entire market towards a very important playing field in the cancer therapeutics market.

From the past few years, the US cancer biosimilar market has continued to observe a focus on the entire transformation of the cancer therapeutics market. The entire transformation caused by the market in the past few years is estimated to be using several technologies such as commercialization and marketing strategic tools and programs that were hardly used for any biologic drug market. It can be estimated for the market that in a short timeframe, has created a novel biotech space, inclining the market and investors towards a strategic important business model in the future years. In addition to this, other driving forces available in the market such as increase in cancer cases and high rate of cancer therapies are likely to accelerate the market towards superior change and drastic arrival of applications for patient use.

Overall market of US cancer biosimilar market is highly driven by the medical progress that is occurring in the country. It can be concluded for the US cancer generics market that the whole market is centric towards cancer patient care. In order to boost the market, government of the country is also promoting the market by forcing on factors such as high influx of local drug makers in the country, increased funds for biosimilar drugs development, aligning the physicians to prescribe biosimilar drugs instead of biologic drugs and many more. Eventually, the market has inclined the entire cancer therapeutics market towards observing less cancer mortality rate and net consumption of the drugs that is high when compared with the market status of biologic drugs for different cancer indications.

As per 'US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 2026' report findings, it is witnessed that there are several different prominent factors that have led to the successful uptake of the market at regional and global level, other than the prominent drivers. Some of the factors involve: high practice for cancer biosimilar at R&D level, high take of clinicians, physicians, payers, manufacturers and legislators on expanding the market trends and opportunities. In addition, difference in the context of development costs, competition, entrant entry and many more in the US when compared with other markets of the world such as EU are also believed to create a landscape that is advancing faster. The entire country is poised towards spiraling research and development for the market, thus inclining the market towards delivering promising opportunities. It is predicted that the US cancer biosimilar market has helped the researchers to navigate through the utmost need of the patients and deliver a course of change that could help the entire cancer therapeutics market at regional and international level offer multiple opportunities.

Contents

1. BIOSIMILIARS: A NEW ERA IN CANCER THERAPEUTICS

1.1 Overview to Cancer Biosimilars
1.2 History of Biosimilars

2. DEVELOPMENT OF BIOSIMILARS

3. NEED OF CANCER BIOSIMILARS IN US

4. US COMPARATIVE PRICE ANALYSIS OF MARKETED CANCER BOSIMILARS

4.1 Avastin
4.2 Herceptin
4.3 Rituximab

5. US REIMBURSEMENT SCENARIO FOR CANCER BIOSIMILARS

5.1 Current Scenario
5.2 Future Potential of Reimbursement Scenario

6. US CANCER BIOSIMILAR MARKET OVERVIEW

6.1 Current Biosimilar Market Scenario
6.2 US Cancer Biosimilar Market
6.3 Off Going Patents: Biosimilar Opportunity Ahead

7. US CANCER BIOSIMILAR MARKET BY PRODUCT

7.1 Rituximab
7.2 Herceptin
7.3 Avastin

8. US POTENTIAL CANCER BIOSIMILARS MARKET OPPORTUNITY BY POPULAR DRUGS PATENT EXPIRY

8.1 Erbitux Biosimilar
8.2 Vectibix Biosimilar
8.3 Yervoy Biosimilar
8.4 Trodelvy Biosimilar
8.5 Perjeta Biosimilar
8.6 Gazyva Biosimilar
8.7 Darzlex Biosimilar
8.8 Xgeva Biosimilar
8.9 Cyramza Biosimilar
8.10 Kadcyla Biosimilar
8.11 Opdivo Biosimilar
8.12 Tagraxofusp Biosimilar
8.13 Tecentriq Biosimilar
8.14 Keytruda Biosimilar
8.15 Imfinzi Biosimilar

9. US BIOSIMILAR CLINICAL PIPELINE BY COMPANY INDICATION & PHASE

9.1 Preclinical
9.2 Phase-I
9.3 Phase-III
9.4 Preregistration
9.5 Registered

10. US MARKETED BIOSIMILAR CLINICAL INSIGHT

11. US CANCER BIOSIMILAR MARKET VS. GLOBAL CANCER BIOSIMILAR MARKET

11.1 Europe Cancer Biosimilar Market
11.2 Japan Cancer Biosimilar Market
11.3 India Cancer Biosimilar Market
11.4 China Cancer Biosimilar Market
11.5 South Korea Cancer Biosimilar Market

12. US BIOSIMILAR VS GENERIC CANCER DRUG MARKET

13. US CANCER BIOSIMILAR MARKET DYNAMICS

13.1 US Cancer Biosimilar Market Drivers
13.2 Barriers to US Biosimilar Market

14. US CANCER BIOSIMILAR FUTURE OUTLOOK

15. COMPETITIVE LANDSCAPE

15.1 Amgen
15.2 AstraZencea
15.3 Biogen
15.4 Coherus Bioscience
15.5 Eli Lilly
15.6 F. Hoffmann-La Roche & Co.
15.7 Merck
15.8 Mylan Pharmaceuticals
15.9 Pfizer
15.10 Teva Pharmaceutical

List Of Figures

LIST OF FIGURES

Figure 1-1: List of Approved Cancer Biosimilars in US
Figure 2-1: Development Pathway for Biosimilar vs. Traditional
Figure 2-2: Development Process for Biosimilars
Figure 3-1: US – Spending on Cancer Care (US$ Billion), 2015-2030
Figure 4-1: Biosimilar Market Relationship
Figure 4-2: US – Avastin, Mvasi & Zirabev Approval Year
Figure 4-3: Avastin – Cost of Supply of 4ml, 16ml, 40ml & 160ml Intravenous Solution (US$), February’2021
Figure 4-4: Mvasi – Cost of Supply of 4ml & 16ml Intravenous Solution (US$), February’2021
Figure 4-5: Zirabev – Cost of Supply of 4ml & 16ml Intravenous Solution (US$), February’2021
Figure 4-6: US - Average per Unit Cost of Avastin, Mvasi & Zirabev (US$), February’2021
Figure 4-7: US – Herceptin & its Biosimilar Approval Year
Figure 4-8: Herceptin – Cost of Supply of 10 Powder Injections & per Unit Cost of 150mg Injection (US$), February’2021
Figure 4-9: Ogivri – Cost of Supply of Intravenous Powder of 150mg & 420mg (US$), February’2021
Figure 4-10: Kanjinti – Cost of Supply of Intravenous Powder of 150mg & 420mg (US$), February’2021
Figure 4-11: Herzuma – Cost of Supply of Intravenous Powder of 150mg & 420mg (US$), February’2021
Figure 4-12: Ontruzant – Cost of Supply of Intravenous Powder of 150mg & 420mg (US$), February’2021
Figure 4-13: Average Cost of 150mg Powder of Herceptin & its Biosimilar (US$), February’2021
Figure 4-14: US - Rituximab, Truxima & Ruxience Approval Year
Figure 4-15: Rituximab – Cost of Supply of 10ml, 50ml & 100ml Intravenous Solution (US$), February’2021
Figure 4-16: Truxima - Cost of Supply of 10ml & 50ml Intravenous Solution (US$), February’2021
Figure 4-17: Ruxience - Cost of Supply of 10ml & 50ml Intravenous Solution (US$), February’2021
Figure 4-18: Average Cost of per Unit Supply of Rituximab, Truxima & Ruxience (US$), February’2021
Figure 4-19: Riabni - Cost of Supply of 10mg & 500mg Intravenous Solution (US$)
Figure 5-1: Kanjinti – Annual Treatment Cost & Reimbursement Cost (US$)
Figure 5-2: Kanjinti- In Pocket Cost & Out Pocket Cost (%)
Figure 5-3: Mvasi – Annual Treatment Cost & Reimbursement Cost (US$)
Figure 5-4: Mvasi - In Pocket Cost & Out Pocket Cost (%)
Figure 5-5: Herzuma - Annual Treatment Cost & Reimbursement Cost (US$)
Figure 5-6: Herzuma - In Pocket Cost & Out Pocket Cost (%)
Figure 5-7: US – Cancer Related Healthcare Spending (US$ Billion), 2019-2030
Figure 5-8: US- Cancer Healthcare Spending by Type
Figure 5-9: Total Cost Savings by Biosimilars by Indication (%), 2019
Figure 5-10: US – Total Cancer Spending & Cost Saving by Biosimilars (US$ Billion), 2019
Figure 5-11: US – Total Cancer Spending & Cost Saving by Biosimilars (US$ Billion), 2030
Figure 6-1: US – Biosimilar Market Size (US$ Billion), 2019-2026
Figure 6-2: US – Cancer Incidence & Mortality (Million), 2020 & 2040
Figure 6-3: US – FDA Approved Biosimilars by Indication
Figure 6-4: US – Cancer Biosimilar Share by Product (%), 2020
Figure 6-5: US – Biosimilar Market by Disease Indication, 2020
Figure 6-6: US – Panitumumab FDA Approval & Patent Expiration Year
Figure 6-7: US – Alemtuzumab FDA Approval & Patent Expiration Year
Figure 6-8: US – Yervoy FDA Approval & Patent Expiration Year
Figure 6-9: US – Parjeta FDA Approval & Patent Expiration Year
Figure 6-10: US – Cyramza FDA Approval & Patent Expiration Year
Figure 6-11: US- Patent Approval & Expiration of Biological Cancer Drugs
Figure 7-1: Rituximab Market by Region (%), 2019
Figure 7-2: US – Ruxience Market Size (US$ Million), 2019 & 2020
Figure 7-3: Ruxience – Market Size by Region (%), 2020
Figure 7-4: US – Ruxience Market Size (US$ Million), 2021-2026
Figure 7-5: US – Rituximab Biosimilar Market Size (US$ Billion), 2020-2026
Figure 7-6: US – Rituximab Market by Product (%), 2019
Figure 7-7: US – Expected Rituximab Market by Product (%), 2026
Figure 7-8: Herceptin – Market Size by Region (%), 2019
Figure 7-9: US- Herceptin Market Size (US$ Billion), 2016-2020
Figure 7-10: US – Herceptin Market by Product (%), 2019
Figure 7-11: US – Expected Herceptin Market by Product (%), 2026
Figure 7-12: US – Kanjinti Market Size (US$ Million), 2019 & 2020
Figure 7-13: Kanjinti – Market Size by Region (%), 2020
Figure 7-14: US – Kanjinti Market Size (US$ Million), 2021-2026
Figure 7-15: US – Herceptin Biosimilar Market Size (US$ Million), 2020-2026
Figure 7-16: Global – Avastin Market Size (US$ Billion), 2016 - 2019
Figure 7-17: Avastin – Market Size by Region (%), 2019
Figure 7-18: US – Mvasi Market Size (US$ Million), 2019 & 2020
Figure 7-19: US – Mvasi Market Size (US$ Million), 2021-2026
Figure 7-20: Zirabev – Market Size by Region (%), 2020
Figure 7-21: US – Zirabev Market Size (US$ Million), 2020-2026
Figure 7-22: US – Avastin Biosimilar Market Size (US$ Million), 2020-2026
Figure 8-1: US – Erbitux Market Size (US$ Million), 2017-2019
Figure 8-2: US – Erbitux Market Size (US$ Million), 2021-2026
Figure 8-3: US – Erbitux Biosimilar Sales Opportunity by 5% of Total Cetuximab Market (US$ Million), 2021-2026
Figure 8-4: US – Erbitux Biosimilar Sales Opportunity by 10% of Total Cetuximab Market (US$ Million), 2021-2026
Figure 8-5: US – Erbitux Biosimilar Sales Opportunity by 15% of Total Cetuximab Market (US$ Million), 2021-2026
Figure 8-6: US – Erbitux Biosimilar Sales Opportunity by 20% of Total Cetuximab Market (US$ Million), 2021-2026
Figure 8-7: US – Erbitux Biosimilar Sales Opportunity by 25% of Total Cetuximab Market (US$ Million), 2021-2026
Figure 8-8: US – Vectibix Market Size (US$ Million), 2018-2020
Figure 8-9: US – Vectibix Market Size (US$ Million), 2021-2026
Figure 8-10: US – Vectibix Biosimilar Sales Opportunity by 5% of Total Panitumumab Market (US$ Million), 2021-2026
Figure 8-11: US – Vectibix Biosimilar Sales Opportunity by 10% of Total Panitumumab Market (US$ Million), 2021-2026
Figure 8-12: US – Vectibix Biosimilar Sales Opportunity by 15% of Total Panitumumab Market (US$ Million), 2021-2026
Figure 8-13: US – Vectibix Biosimilar Sales Opportunity by 20% of Total Panitumumab Market (US$ Million), 2021-2026
Figure 8-14: US – Vectibix Biosimilar Sales Opportunity by 25% of Total Panitumumab Market (US$ Million), 2021-2026
Figure 8-15: US – Yervoy Market Size (US$ Million), 2017-2020
Figure 8-16: US – Yervoy Market Size (US$ Million), 2021-2026
Figure 8-17: US – Yervoy Biosimilar Sales Opportunity by 5% of Total Ipilimumab Market (US$ Million), 2024-2026
Figure 8-18: US – Yervoy Biosimilar Sales Opportunity by 10% of Total Ipilimumab Market (US$ Million), 2024-2026
Figure 8-19: US – Yervoy Biosimilar Sales Opportunity by 15% of Total Ipilimumab Market (US$ Million), 2024-2026
Figure 8-20: US – Yervoy Biosimilar Sales Opportunity by 20% of Total Ipilimumab Market (US$ Million), 2024-2026
Figure 8-21: US – Yervoy Biosimilar Sales Opportunity by 25% of Total Ipilimumab Market (US$ Million), 2024-2026
Figure 8-22: US - Trodelvy Quarterly Sales Value (US$ Million), Q2 – Q4, 2020
Figure 8-23: US – Trodelvy Market Size (US$ Million), 2021-2026
Figure 8-24: US – Trodelvy Biosimilar Sales Opportunity by 5% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026
Figure 8-25: US – Trodelvy Biosimilar Sales Opportunity by 10% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026
Figure 8-26: US – Trodelvy Biosimilar Sales Opportunity by 15% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026
Figure 8-27: US – Trodelvy Biosimilar Sales Opportunity by 20% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026
Figure 8-28: US – Trodelvy Biosimilar Sales Opportunity by 25% of Total Sacituzumab Govitecan Market (US$ Million), 2024-2026
Figure 8-29: US – Perjeta Market Size (US$/CHF Million), 2018-2020
Figure 8-30: US – Perjeta Market Size (US$ Million), 2021-2026
Figure 8-31: US – Perjeta Biosimilar Sales Opportunity by 5% of Total Pertuzumab Market (US$ Million)
Figure 8-32: US – Perjeta Biosimilar Sales Opportunity by 10% of Total Pertuzumab Market (US$ Million)
Figure 8-33: US – Perjeta Biosimilar Sales Opportunity by 15% of Total Pertuzumab Market (US$ Million)
Figure 8-34: US – Perjeta Biosimilar Sales Opportunity by 20% of Total Pertuzumab Market (US$ Million)
Figure 8-35: US – Perjeta Biosimilar Sales Opportunity by 25% of Total Pertuzumab Market (US$ Million)
Figure 8-36: US - Gazyva Market Size (US$/CHF Million), 2017-2020
Figure 8-37: US – Gazyva Market Size (US$ Million), 2021-2026
Figure 8-38: US – Gazyva Biosimilar Sales Opportunity by 5% of Total Obinutuzumab Market (US$ Million)
Figure 8-39: US – Gazyva Biosimilar Sales Opportunity by 10% of Total Obinutuzumab Market (US$ Million)
Figure 8-40: US – Gazyva Biosimilar Sales Opportunity by 15% of Total Obinutuzumab Market (US$ Million)
Figure 8-41: US – Gazyva Biosimilar Sales Opportunity by 20% of Total Obinutuzumab Market (US$ Million)
Figure 8-42: US – Gazyva Biosimilar Sales Opportunity by 25% of Total Obinutuzumab Market (US$ Million)
Figure 8-43: US – Darzalex Market Size (US$ Million), 2018-2020
Figure 8-44: US – Darzalex Market Size (US$ Million), 2021-2026
Figure 8-45: US – Darzalex Biosimilar Sales Opportunity by 5% of Total Daratumumab Market (US$ Million)
Figure 8-46: US – Darzalex Biosimilar Sales Opportunity by 10% of Total Daratumumab Market (US$ Million)
Figure 8-47: US – Darzalex Biosimilar Sales Opportunity by 15% of Total Daratumumab Market (US$ Million)
Figure 8-48: US – Darzalex Biosimilar Sales Opportunity by 20% of Total Daratumumab Market (US$ Million)
Figure 8-49: US – Darzalex Biosimilar Sales Opportunity by 25% of Total Daratumumab Market (US$ Million)
Figure 8-50: US – Xgeva Market Size (US$ Million), 2018-2020
Figure 8-51: US – Xgeva Market Size (US$ Million), 2021-2026
Figure 8-52: US – Xgeva Biosimilar Sales Opportunity by 5% of Total Denosumab Market (US$ Million)
Figure 8-53: US – Xgeva Biosimilar Sales Opportunity by 10% of Total Denosumab Market (US$ Million)
Figure 8-54: US – Xgeva Biosimilar Sales Opportunity by 15% of Total Denosumab Market (US$ Million)
Figure 8-55: US – Xgeva Biosimilar Sales Opportunity by 20% of Total Denosumab Market (US$ Million)
Figure 8-56: US – Xgeva Biosimilar Sales Opportunity by 25% of Total Denosumab Market (US$ Million)
Figure 8-57: US – Cyramza Market Size (US$ Million), 2017-2020
Figure 8-58: US – Cyramza Market Size (US$ Million), 2021-2026
Figure 8-59: US – Cyramza Biosimilar Sales Opportunity by 5% of Total Ramucirumab Market (US$ Million)
Figure 8-60: US – Cyramza Biosimilar Sales Opportunity by 10% of Total Ramucirumab Market (US$ Million)
Figure 8-61: US – Cyramza Biosimilar Sales Opportunity by 15% of Total Ramucirumab Market (US$ Million)
Figure 8-62: US – Cyramza Biosimilar Sales Opportunity by 20% of Total Ramucirumab Market (US$ Million)
Figure 8-63: US – Cyramza Biosimilar Sales Opportunity by 25% of Total Ramucirumab Market (US$ Million)
Figure 8-64: US – Kadcyla Market Size (US$/CHF Million), 2018-2020
Figure 8-65: US – Kadcyla Market Size (US$ Million), 2021-2026
Figure 8-66: US – Kadcyla Biosimilar Sales Opportunity by 5% of Total Trastuzumab Emtansine Market (US$ Million)
Figure 8-67: US – Kadcyla Biosimilar Sales Opportunity by 10% of Total Trastuzumab Emtansine Market (US$ Million)
Figure 8-68: US – Kadcyla Biosimilar Sales Opportunity by 15% of Total Trastuzumab Emtansine Market (US$ Million)
Figure 8-69: US – Kadcyla Biosimilar Sales Opportunity by 20% of Total Trastuzumab Emtansine Market (US$ Million)
Figure 8-70: US – Kadcyla Biosimilar Sales Opportunity by 25% of Total Trastuzumab Emtansine Market (US$ Million)
Figure 8-71: US – Opdivo Market Size (US$ Million), 2017-2020
Figure 8-72: US – Opdivo Market Size (US$ Million), 2021-2026
Figure 8-73: US – Opdivo Biosimilar Sales Opportunity by 5% of Total Nivolumab Market (US$ Million)
Figure 8-74: US – Opdivo Biosimilar Sales Opportunity by 10% of Total Nivolumab Market (US$ Million)
Figure 8-75: US – Opdivo Biosimilar Sales Opportunity by 15% of Total Nivolumab Market (US$ Million)
Figure 8-76: US – Opdivo Biosimilar Sales Opportunity by 20% of Total Nivolumab Market (US$ Million)
Figure 8-77: US – Opdivo Biosimilar Sales Opportunity by 25% of Total Nivolumab Market (US$ Million)
Figure 8-78: US – Tagraxousp Market Size (US$ Million), 2019 & 2020
Figure 8-79: US – Tagraxousp Market Size (US$ Million), 2021-2026
Figure 8-80: US – Tagraxousp Biosimilar Sales Opportunity by 5% of Total Elzonris Market (US$ Million)
Figure 8-81: US – Tagraxousp Biosimilar Sales Opportunity by 10% of Total Elzonris Market (US$ Million)
Figure 8-82: US – Tagraxousp Biosimilar Sales Opportunity by 15% of Total Elzonris Market (US$ Million)
Figure 8-83: US – Tagraxousp Biosimilar Sales Opportunity by 20% of Total Elzonris Market (US$ Million)
Figure 8-84: US – Tagraxousp Biosimilar Sales Opportunity by 25% of Total Elzonris Market (US$ Million)
Figure 8-85: US – Tecentriq Market Size (US$/CHF Million), 2018-2020
Figure 8-86: US – Tecentriq Market Size (US$ Million), 2021-2026
Figure 8-87: US – Tecentriq Biosimilar Sales Opportunity by 5% of Total Atezolizumab Emtansine Market (US$ Million)
Figure 8-88: US – Tecentriq Biosimilar Sales Opportunity by 10% of Total Atezolizumab Emtansine Market (US$ Million)
Figure 8-89: US – Tecentriq Biosimilar Sales Opportunity by 15% of Total Atezolizumab Emtansine Market (US$ Million)
Figure 8-90: US – Tecentriq Biosimilar Sales Opportunity by 20% of Total Atezolizumab Emtansine Market (US$ Million)
Figure 8-91: US – Tecentriq Biosimilar Sales Opportunity by 25% of Total Atezolizumab Emtansine Market (US$ Million)
Figure 8-92: US – Keytruda Market Size (US$ Million), 2018-2020
Figure 8-93: US – Keytruda Market Size (US$ Billion), 2021-2026
Figure 8-94: US – Keytruda Biosimilar Sales Opportunity by 5% of Total Pembrolizumab Emtansine Market (US$ Million)
Figure 8-95: US – Keytruda Biosimilar Sales Opportunity by 10% of Total Pembrolizumab Emtansine Market (US$ Million)
Figure 8-96: US – Keytruda Biosimilar Sales Opportunity by 15% of Total Pembrolizumab Emtansine Market (US$ Million)
Figure 8-97: US – Keytruda Biosimilar Sales Opportunity by 20% of Total Pembrolizumab Emtansine Market (US$ Million)
Figure 8-98: US – Keytruda Biosimilar Sales Opportunity by 25% of Total Pembrolizumab Emtansine Market (US$ Million)
Figure 8-99: US – Keytruda Market Size (US$ Million), 2018-2020
Figure 8-100: US – Imfinzi Market Size (US$ Million), 2021-2026
Figure 8-101: US – Imfinzi Biosimilar Sales Opportunity by 5% of Total Durvalumab Emtansine Market (US$ Million)
Figure 8-102: US – Imfinzi Biosimilar Sales Opportunity by 10% of Total Durvalumab Emtansine Market (US$ Million)
Figure 8-103: US – Imfinzi Biosimilar Sales Opportunity by 15% of Total Durvalumab Emtansine Market (US$ Million)
Figure 8-104: US – Imfinzi Biosimilar Sales Opportunity by 20% of Total Durvalumab Emtansine Market (US$ Million)
Figure 8-105: US – Imfinzi Biosimilar Sales Opportunity by 25% of Total Durvalumab Emtansine Market (US$ Million)
Figure 11-1: US - New Cancer Cases by Region (Millions), 2020 & 2040
Figure 11-2: Approved Biosimilars in US & Europe
Figure 11-3: Europe – Biosimilar Market Size (US$ Billion), 2017-2020
Figure 11-4: Europe – Expected Biosimilar Market Size (US$ Billion), 2021-2026
Figure 11-5: Europe – Oncology Biosimilar Market Size (US$ Billion), 2017 - 2020
Figure 11-6: Japan – Emerging Cancer Cases & Deaths (Million), 2020 & 2040
Figure 11-7: Approved Biosimilars in US & Japan
Figure 11-8: First Biosimilar Approval Year by Region
Figure 11-9: Oncology Biosimilar Approved by Region
Figure 11-10: Japan – Cancer Biosimilar Market Size (US$ Million), 2018-2020
Figure 11-11: Japan – Expected Oncology Biosimilar Market Size (US$ Billion), 2021-2026
Figure 11-12: India – New Emerging Cases & Death by Cancer (Million), 2020 & 2040
Figure 11-13: Approved Biosimilars in India & US
Figure 11-14: India – Oncology Biosimilar Market Size (US$ Million), 2016-2019
Figure 11-15: India – Rituximab Biosimilar Price by Brand (USD/INR)
Figure 11-16: India – Pipeline of Biosimilars by Stage of Development
Figure 11-17: India – Pipeline of Biosimilars by Stage of Development (%)
Figure 11-18: India - Cancer Biosimilar Market Size (US$ Million), 2020-2026
Figure 11-19: China – New Cancer Cases & Associated Deaths (Million), 2020 & 2040
Figure 11-20: China – Biological Drugs Market Size (US$/Yuan Billion), 2019-2026
Figure 11-21: First Biosimilar Approval Year by Region
Figure 11-22: Total Biosimilar Approved by Region
Figure 11-23: China – Biosimilar Market Size (US$ Billion), 2019-2026
Figure 11-24: South Korea – Cancer Incidences, 2020 & 2040
Figure 11-25: South Korea – Cancer Mortality, 2020 & 2040
Figure 11-26: South Korea – Biological Drug Market Size (US$ Billion), 2016-2021
Figure 11-27: First Biosimilar Approval Year by Region
Figure 11-28: Number of Approved Biosimilars by Region
Figure 11-29: Approved Oncology Biosimilars by Region
Figure 11-30: Approved Oncology Biosimilars by Product
Figure 12-1: US – Annual Savings from Generics (US$ Billion), 2015-2019
Figure 12-2: US – Cost Savings in 10 years by Type (US$ Billion)
Figure 12-3: US – Generic vs Biosimilar Drug Market Size (US$ Billion), 2019-2026
Figure 13-1: Zirabev – Potential Cost Savings per Cycle, Monthly & Annualy (US$)
Figure 13-2: US- New Cancer Cases, 2020 & 2040
Figure 13-3: US- Cancer Mortality, 2020 & 2040
Figure 13-4: Kanjinti – Total Treatment Cost & Reimbursement Cost (US$)
Figure 13-5: Kanjinti- In Pocket Cost & Out Pocket Cost (%)
Figure 13-6: US – Biosimilar Market Drivers
Figure 13-7: US – Biosimilar Market Barriers
Figure 13-8: Manufacturing Process of Biosimilars